Background: Alzheimer’s disease (AD) is a neurodegenerative disorder, whose treatment is limited to drugs that offer comfort to the patient. Immunotherapy with monoclonal antibodies (mAbs) has been the subject of a study with the promise of reversing cognitive deficits. In this scenario, we conducted a systematic review to elucidate aspects about the effectiveness of such treatment. Objectives: Analyze the prognostic of patients with AD through immunotherapy using anti-amilody mAbs. Methods: It was used the PubMed database using the descriptors: “Amyloid beta-Peptides AND Alzheimer disease AND Immunotherapy”. Filters: clinical trial, randomized controlled trial. 6 articles from 2015 to 2021 were selected. Inclusion criteria: (1) mAbs as treatment for AD; (2) Analyze the prognostic. Results: The immunotherapy with bapineuzumab and solanezumab didn’t showed no statistically significant difference between the groups of bapineuzumab 0,5 mg / kg (p = 0,979) and placebo (p = 0,973) and a change of 6.65 in the solanezumab group and 7.44 in the placebo group (difference, −0.80; P = 0 , 10). However, subcutaneous treatment of bapineuzumab exhibited fewer abnormalities of images related to amyloid with edema or effusion (AIRA), so, better tolerated compared to intravenous treatment. In the study with the ABvac40 vaccine, about 92% of the individuals in the test group developed specific anti-Aβ 40 antibodies. Conclusion: Bapineuzumab and solanezumab didn’t achieve significant results in the reduction of cognitive decline, however bapineuzumab enabled the prevention of Aβ aggregation. However, the use of mAbs can trigger collateral effects, requiring an individual analysis.

Background: Dravet syndrome (DS) is a rare treatment-resistant epileptic encephalopathy, with a high mortality rate, resulting from mutations in the SCN1A gene (encoding the α1 subunit of the NaV1.1 channel). Studies show that cannabidiol is effective in reducing the frequency of seizures. Objective: Analyze the efficacy of cannabidiol for the treatment of refractory epilepsy in DS. Methods: In April 2021, the PubMed database was queried to search for the terms “Cannabidiol” AND “Dravet Syndrome”, with the filters: Clinical trial, Randomized controlled trial and the articles were limited to the last 5 years. With this, 8 articles were found, of which 3 were selected. Exclusion criteria: (1) articles that didn’t evaluate the effectiveness of treatment (2) review articles. Results: A randomized, double-blind study of 120 patients, which a dose of 20 mg/kg/day was used, found that cannabidiol use led to lower frequency of seizures, reducing from 12, 4 to 5.9 seizures per month; and 5% of participants were seizure-free. A similar reduction was documented by an open clinical trial, which there was a reduction of 39.5% in total seizure frequency and 2.9% were seizure-free. Additionally, another randomized, double-blind study reported a percentage reduction in seizure frequency of 48.7% for the group of patients given 10 mg/kg/day, and 45.7% for the group given 20 mg/kg/day. Conclusion: In DS patients, cannabidiol shows efficacy to reduce the frequency of seizures. However, more studies are needed to validate its application.